ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO835

The Vitamin D Metabolite Ratio and Incident Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1500 Health Maintenance, Nutrition, and Metabolism

Authors

  • Cheng, Jonathan, University of California San Diego, La Jolla, California, United States
  • Hoofnagle, Andrew N., University of Washington, Seattle, Washington, United States
  • Katz, Ronit, University of Washington, Seattle, Washington, United States
  • Hsu, Simon, University of Washington, Seattle, Washington, United States
  • Kado, Deborah M., Stanford Medicine, Stanford, California, United States
  • Budoff, Matthew Jay, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Kestenbaum, Bryan R., University of Washington, Seattle, Washington, United States
  • Michos, Erin D., Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Miller, Lindsay M., University of California San Diego, La Jolla, California, United States
  • Ix, Joachim H., University of California San Diego, La Jolla, California, United States
  • de Boer, Ian H., University of Washington, Seattle, Washington, United States
  • Ginsberg, Charles, University of California San Diego, La Jolla, California, United States
Background

Vitamin D deficiency has been linked to cardiovascular disease (CVD) with mixed results. The vitamin D metabolite ratio (VMR), the ratio of 24,25(OH)2D to 25(OH)D, has shown stronger associations with bone health and mortality than 25(OH)D alone. Our study assessed the association between the VMR and CVD outcomes.

Methods

We evaluated 6,313 Multi-Ethnic Study of Atherosclerosis (MESA) participants without CVD using Cox regression to test the associations of both VMR and 25(OH)D with incident CVD (including myocardial infarction, resuscitated cardiac arrest, stroke, coronary heart disease death, and stroke death), heart failure (HF), and cardiovascular mortality. We adjusted models for age, gender, race, physical activity, BMI, smoking, diabetes, blood pressure condition and medication use, C-reactive protein, cholesterol levels and medication use, triglycerides, kidney function, parathyroid hormone, fibroblast growth factor 23, calcium, and phosphate.

Results

The study participants had a mean age of 62, with 53% of them being female. The cohort was 38% White, 28% Black, 22% Hispanic, and 12% Chinese. The mean (SD) 25(OH)D level was 22.7 (11.0) ng/mL, and the mean VMR was 15.2 (5.0). In fully adjusted models, a two-fold increase in VMR was associated with a 24% reduction in incident CVD (HR: 0.76, 95% CI: 0.65-0.88). However, there was no association between the VMR and HF (0.98, 0.78-1.24), or cardiovascular mortality (0.96, 0.77-1.21). 25(OH)D was not significantly associated with any CVD outcome.

Conclusion

In a multi-ethnic cohort, VMR was significantly associated with reduced incident CVD, but not HF or cardiovascular mortality over 15 years of follow-up. The results suggest that VMR may provide greater insight into vitamin D metabolism compared with 25(OH)D levels alone.

Association of VMR and 25(OH)D with Cardiovascular Outcomes: Fully Adjusted Model
OutcomeHR (95% CI)N Events / N at RiskMean Follow Up Time (Years)p-value
VMR* 
CVD0.76 (0.65, 0.88)800 / 6,30314.5<0.001
HF0.98 (0.78, 1.24)398 / 6,30114.70.891
Cardiovascular Mortality0.96 (0.77, 1.21)413 / 6,31016.00.754
25(OH)D* 
CVD0.95 (0.85, 1.06)801 / 6,30614.50.395
HF1.03 (0.88, 1.2)398 / 6,30414.70.748
Cardiovascular Mortality0.91 (0.78, 1.06)414 / 6,31316.00.237

*Per two-fold increase

Funding

  • NIDDK Support